利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

767 条记录 (耗时 0.026 秒)

    Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
    10.
    发明授权
    Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders 有权

    公开(公告)号：US11318129B2

    公开(公告)日：2022-05-03

    申请号：US16773723

    申请日：2020-01-27

    申请人： Ardelyx, Inc.

    发明人： Dominique Charmot ,  Marc Navre ,  Christopher Carreras ,  Noah Bell ,  Michael Robert Leadbetter ,  Jeffrey W. Jacobs

    IPC分类号： A61K31/4725 ,  A61K45/06 ,  A61K9/00 ,  A61K31/472 ,  A61K47/60 ,  A61K31/18 ,  A61K31/675 ,  A61K31/517 ,  C07D217/04 ,  C07F9/62 ,  C07F9/38 ,  C07F9/40 ,  C07D217/14 ,  C07D217/16 ,  A61K31/662

    摘要： The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.